A detailed history of Anchor Investment Management, LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Anchor Investment Management, LLC holds 2,141 shares of VRTX stock, worth $1 Million. This represents 0.09% of its overall portfolio holdings.

Number of Shares
2,141
Previous 1,973 8.51%
Holding current value
$1 Million
Previous $803 Million 11.48%
% of portfolio
0.09%
Previous 0.09%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$407.69 - $446.08 $68,491 - $74,941
168 Added 8.51%
2,141 $895 Million
Q4 2023

Jan 02, 2024

BUY
$343.0 - $410.68 $676,739 - $810,271
1,973 New
1,973 $803 Million
Q3 2023

Jan 02, 2024

BUY
$338.18 - $362.46 $127,832 - $137,009
378 Added 29.12%
1,676 $583 Million
Q2 2023

Jan 02, 2024

BUY
$314.42 - $351.91 $199,027 - $222,759
633 Added 95.19%
1,298 $457 Million
Q1 2023

Jan 02, 2024

BUY
$283.23 - $323.1 $11,612 - $13,247
41 Added 6.57%
665 $210 Million
Q4 2022

Jan 02, 2024

SELL
$285.76 - $321.48 $385,490 - $433,676
-1,349 Reduced 68.37%
624 $180 Million
Q3 2022

Jan 02, 2024

SELL
$273.83 - $305.53 $537,528 - $599,755
-1,963 Reduced 99.49%
10 $2.9 Million
Q3 2021

Jan 02, 2024

SELL
$181.39 - $202.99 $356,068 - $398,469
-1,963 Reduced 99.49%
10 $1.81 Million
Q2 2021

Jan 02, 2024

SELL
$187.49 - $221.1 $126,555 - $149,242
-675 Reduced 98.54%
10 $2.02 Million
Q1 2021

Jan 02, 2024

BUY
$207.02 - $241.31 $108,685 - $126,687
525 Added 328.13%
685 $147 Million
Q4 2020

Jan 02, 2024

BUY
$207.01 - $276.09 $23,806 - $31,750
115 Added 255.56%
160 $37.8 Million
Q3 2020

Jan 02, 2024

SELL
$255.65 - $303.1 $492,893 - $584,376
-1,928 Reduced 97.72%
45 $12.2 Million
Q2 2020

Jan 02, 2024

SELL
$225.48 - $295.8 $442,617 - $580,655
-1,963 Reduced 99.49%
10 $2.9 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $120B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Anchor Investment Management, LLC Portfolio

Follow Anchor Investment Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Anchor Investment Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Anchor Investment Management, LLC with notifications on news.